These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22690822)

  • 1. Nonamorphism in flufenamic acid and a new record for a polymorphic compound with solved structures.
    López-Mejías V; Kampf JW; Matzger AJ
    J Am Chem Soc; 2012 Jun; 134(24):9872-5. PubMed ID: 22690822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymer-induced heteronucleation of tolfenamic acid: structural investigation of a pentamorph.
    López-Mejías V; Kampf JW; Matzger AJ
    J Am Chem Soc; 2009 Apr; 131(13):4554-5. PubMed ID: 19334766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stabilization of metastable flufenamic acid by inclusion of mefenamic acid: solid solution or epilayer?
    Lee EH; Byrn SR
    J Pharm Sci; 2010 Sep; 99(9):4013-22. PubMed ID: 20589947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of solid state properties on the dissolution performance of flufenamic acid.
    Maestrelli F; Rossi P; Paoli P; De Luca E; Mura P
    J Pharm Biomed Anal; 2020 Feb; 180():113058. PubMed ID: 31881398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative study of solid-state acid-base reactions between polymorphs of flufenamic acid and magnesium oxide using X-ray powder diffraction.
    Chen X; Stowell JG; Morris KR; Byrn SR
    J Pharm Biomed Anal; 2010 Mar; 51(4):866-74. PubMed ID: 19906502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystal quality and physical reactivity in the case of flufenamic acid (FFA).
    Li H; Wen H; Stowell JG; Morris KR; Byrn SR
    J Pharm Sci; 2010 Sep; 99(9):3839-48. PubMed ID: 20589945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulatory Effects of Soluplus® on Flufenamic Acid β-Cyclodextrin Supramolecular Complex: Physicochemical Characterization and Pre-clinical Anti-inflammatory Assessment.
    Alshehri S; Imam SS; Altamimi MA; Hussain A; Shakeel F; Alshehri A
    AAPS PharmSciTech; 2020 May; 21(5):145. PubMed ID: 32430787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flufenamic acid as an ion channel modulator.
    Guinamard R; Simard C; Del Negro C
    Pharmacol Ther; 2013 May; 138(2):272-84. PubMed ID: 23356979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thermodynamic properties of flufenamic and niflumic acids--specific and non-specific interactions in solution and in crystal lattices, mechanism of solvation, partitioning and distribution.
    Perlovich GL; Surov AO; Bauer-Brandl A
    J Pharm Biomed Anal; 2007 Nov; 45(4):679-87. PubMed ID: 17336023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A [24-MC-6] zinc metallacoronate with a nonsteroidal antiinflammatory drug as the constructing ligand.
    Tarushi A; Kastanias F; Psycharis V; Raptopoulou CP; Psomas G; Kessissoglou DP
    Inorg Chem; 2012 Jul; 51(14):7460-2. PubMed ID: 22758372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissolution Behavior of Flufenamic Acid in Heated Mixtures with Nanocellulose.
    Mantas A; Mihranyan A
    Molecules; 2020 Mar; 25(6):. PubMed ID: 32168901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insight into Flufenamic Acid Cocrystal Dissolution in the Presence of a Polymer in Solution: from Single Crystal to Powder Dissolution.
    Guo M; Wang K; Qiao N; Fábián L; Sadiq G; Li M
    Mol Pharm; 2017 Dec; 14(12):4583-4596. PubMed ID: 29091446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crystal anisotropy explains structure-mechanics impact on tableting performance of flufenamic acid polymorphs.
    Jain A; Shah HS; Johnson PR; Narang AS; Morris KR; Haware RV
    Eur J Pharm Biopharm; 2018 Nov; 132():83-92. PubMed ID: 30213565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimation of the transition temperature for an enantiotropic polymorphic system from the transformation kinetics monitored using Raman spectroscopy.
    Hu Y; Wikström H; Byrn SR; Taylor LS
    J Pharm Biomed Anal; 2007 Nov; 45(4):546-51. PubMed ID: 17851013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigating the Influence of Polymers on Supersaturated Flufenamic Acid Cocrystal Solutions.
    Guo M; Wang K; Hamill N; Lorimer K; Li M
    Mol Pharm; 2016 Sep; 13(9):3292-307. PubMed ID: 27494289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding the Effects of a Polymer on the Surface Dissolution of Pharmaceutical Cocrystals Using Combined Experimental and Molecular Dynamics Simulation Approaches.
    Kirubakaran P; Wang K; Rosbottom I; Cross RBM; Li M
    Mol Pharm; 2020 Feb; 17(2):517-529. PubMed ID: 31887053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Copper(II) interacting with the non-steroidal antiinflammatory drug flufenamic acid: structure, antioxidant activity and binding to DNA and albumins.
    Tolia C; Papadopoulos AN; Raptopoulou CP; Psycharis V; Garino C; Salassa L; Psomas G
    J Inorg Biochem; 2013 Jun; 123():53-65. PubMed ID: 23528572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal structures of three classes of non-steroidal anti-inflammatory drugs in complex with aldo-keto reductase 1C3.
    Flanagan JU; Yosaatmadja Y; Teague RM; Chai MZ; Turnbull AP; Squire CJ
    PLoS One; 2012; 7(8):e43965. PubMed ID: 22937138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphology study of progesterone polymorphs prepared by polymer-induced heteronucleation (PIHn).
    Araya-Sibaja AM; Fandaruff C; Campos CE; Soldi V; Cardoso SG; Cuffini SL
    Scanning; 2013; 35(4):213-21. PubMed ID: 23034679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crystal structures of prostaglandin D(2) 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin.
    Lovering AL; Ride JP; Bunce CM; Desmond JC; Cummings SM; White SA
    Cancer Res; 2004 Mar; 64(5):1802-10. PubMed ID: 14996743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.